Christophe Le Tourneau
克里斯托夫·勒图尔诺
MD, PhD
Head, Department of Drug Development and Innovation (D3i); Medical Oncologist; Professor, University of Paris药物开发与创新科（D3i）主任；肿瘤内科医生；巴黎大学教授
👥Biography 个人简介
Christophe Le Tourneau, MD, PhD is Head of the Department of Drug Development and Innovation (D3i) at Institut Curie in Paris, one of Europe's foremost cancer research institutions, and Professor at the University of Paris. He is internationally recognized for designing and leading the SHIVA trial — the first randomized phase II trial to rigorously test the core premise of personalized oncology: whether molecularly matched targeted therapy chosen on the basis of tumor molecular profiling outperforms physician's choice chemotherapy regardless of histology. SHIVA enrolled 195 patients with advanced solid tumors across multiple histologies and randomly assigned them (2:1) to targeted therapy matched to a pre-specified molecular alteration versus conventional therapy; the trial reported no significant difference in progression-free survival (HR 0.88; p=0.41) between matched and unmatched arms, generating enormous scientific debate about the sufficiency of mutation-matching alone without co-alteration context and informing the design of subsequent precision oncology basket studies. Beyond SHIVA, Dr. Le Tourneau directs a highly active phase I program at Institut Curie, has led multiple first-in-human and early-phase trials in head and neck squamous cell carcinoma, and is a leading European advocate for adaptive Bayesian trial designs in drug development. He has served on ESMO, AACR, and French regulatory advisory boards, and has authored over 300 peer-reviewed publications.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
SHIVA Trial — First Randomized Test of Molecularly Guided Off-Label Therapy
Designed and led the SHIVA trial (Lancet Oncology 2015), the first randomized controlled trial (RCT) to directly test whether tumor molecular profiling-guided targeted therapy selection improves progression-free survival compared to conventional physician-choice therapy in unselected advanced solid tumor patients. SHIVA enrolled 195 patients who underwent comprehensive molecular profiling (CGH, gene mutation hotspot panel, IHC for hormone receptors); 99 were randomized to matched targeted therapy and 96 to conventional therapy. The primary endpoint (PFS) was not met (HR 0.88; 95% CI 0.65–1.19; p=0.41), generating the foundational scientific finding — now the basis of precision oncology trial design consensus — that single molecular alteration matching without co-mutation context, tumor microenvironment consideration, and pharmacologic target engagement verification is insufficient to improve outcomes, shaping the next generation of platform and adaptive basket trial design.
Adaptive Bayesian Trial Design Leadership in Europe
Led the design and implementation of multiple adaptive Bayesian dose-escalation trials at Institut Curie, including the CRM (continual reassessment method) and BLRM (Bayesian logistic regression model) for phase I dose escalation, and contributed to the design of seamless adaptive phase I/II trials incorporating biomarker-adaptive expansion cohorts. Co-authored the ESMO consensus guidelines on adaptive trial design for early drug development, advocated for regulatory acceptance of adaptive methods at EMA advisory meetings, and contributed simulation-based evidence demonstrating the efficiency and patient-safety advantages of model-based over rule-based dose-escalation designs in the European regulatory context.
Head and Neck Cancer Phase I/II Drug Development
Established Institut Curie as a leading center for phase I and II drug development in head and neck squamous cell carcinoma (HNSCC), leading multiple early-phase trials of PD-1/PD-L1 checkpoint inhibitors, EGFR inhibitor combinations, DNA damage response agents, and novel targeted agents in recurrent/metastatic HNSCC. Contributed translational biomarker analyses characterizing the role of HPV status, TMB, PD-L1 expression, TGF-β signaling, and immune cell infiltrates as predictors of immune checkpoint inhibitor response in HNSCC, and developed a systematic molecular profiling approach for HNSCC patients entering early-phase trials at Institut Curie.
Institut Curie D3i Drug Development Program — European Phase I Hub
Built and leads the D3i (Departement de Recherche Translationnelle et Drug Innovation) at Institut Curie, which operates one of France's most active academic phase I programs spanning solid tumor histologies including breast, lung, colorectal, and HNSCC. The D3i integrates molecular prescreening, mandatory tumor biopsies, pharmacokinetic and pharmacogenomic sampling, and ctDNA monitoring into a systematic clinical trial platform, serving as the lead site for multiple European EORTC and global pharmaceutical sponsor phase I trials and mentoring the next generation of European drug development oncologists.
Representative Works 代表性著作
Molecularly Targeted Therapy Based on Tumour Molecular Profiling versus Conventional Therapy for Advanced Cancer (SHIVA)
Lancet Oncology (2015)
Landmark SHIVA randomized phase II trial demonstrating no PFS benefit from molecular alteration-matched targeted therapy versus conventional therapy, defining the limitations of simple mutation-matching and reshaping precision oncology trial design paradigms.
Randomized Phase II Trial of Cetuximab Plus Docetaxel versus Cetuximab Plus Docetaxel and Cisplatin as First-Line Treatment of Recurrent/Metastatic HNSCC
Annals of Oncology (2015)
Phase II HNSCC trial at Institut Curie characterizing EGFR inhibitor combination efficacy and translational biomarkers in recurrent/metastatic disease, contributing to HNSCC phase I/II program development.
Treatment Beyond Progression in Cancer Patients: A Position Paper from the ESMO Precision Oncology Working Group
Annals of Oncology (2019)
ESMO consensus position on treatment beyond progression in precision oncology trials, providing clinical and regulatory guidance for interpreting atypical response patterns in molecularly selected early-phase studies.
Dose Escalation Methods in Phase I Cancer Clinical Trials
Journal of the National Cancer Institute (2009)
Systematic review and comparative analysis of dose-escalation methodologies in phase I oncology, demonstrating the statistical and patient-safety advantages of model-based methods over traditional 3+3 design — a foundational reference in phase I methodology.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 克里斯托夫·勒图尔诺 的研究动态
Follow Christophe Le Tourneau's research updates
留下邮箱，当我们发布与 Christophe Le Tourneau（Institut Curie; University of Paris）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment